Integrated in vitro and in silico evaluation of adamantane-1,2,3-triazole hybrids as potential α-glucosidase inhibitors.

Authors

Aman Ragshaniya, Vivek Asati, Jayant Sindhu, Sonika Asija, Kashmiri Lal

Published in

Future medicinal chemistry. Pages 1-12. Jul 14, 2026. Epub Jul 14, 2026.

Abstract

To find for lead compounds, efficiently defeating diabetes mellitus, prompted us to the synthesis of a new library of adamantane‑appended 1,2,3-triazole hybrid conjugates (AT1-AT18).
The current synthesis of adamantane-appended 1,2,3-triazoles was performed by using Cu(I)-catalyzed azide-alkyne cycloaddition reaction. The hybrids were structurally characterized via ¹H, ¹³C NMR, FTIR, and mass spectrometry. The hybrids were evaluated for their inhibitory potential for α-glucosidase enzyme, along with in silico activity, i.e., molecular docking, molecular dynamics simulations, and ADME (absorption, distribution, metabolism, and excretion).
Hybrid AT5 (IC₅₀ 5.5 ± 0.87 µM) showed maximum inhibition potential against α-glucosidase enzyme, which may be risen from the methyl substitution on phenyl ring. The results were compared with the reference, acarbose (IC₅₀ 13.5 ± 0.32 µM). The docking studies using PDB:3L4U revealed that the hybrid AT5 demonstrated a docking score -7.656, which was better than alkyne, i.e., -3.894. Ligand stability analysis explored by using molecular dynamics demonstrated the useful findings such as RMSD <2 Å, 0-2 H-bonds, for hybrid AT5, highlighting the stabilization contribution of triazole unit.
The hybrid AT5 may be used as potential lead compound after necessary structural modifications.

PMID:
42444437
Bibliographic data and abstract were imported from PubMed on 14 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.